HIGH GRADE SEROUS OVARIAN CARCINOMA -A CLINICAL CHALLENGE OF REPRODUCTIVE AGE GROUP

Dr. M. Jyothsna Priyanka, Dr. Mvvn Suresh Babu

Abstract


High grade serous ovarian carcinoma (HGSOC) is one of the five major histological types of ovarian carcinoma associated with specific biology and worst prognosis. HGSOC is common among post-menopausal compared to premenopausal women. In a span of 1 1/2 year in our institution two cases of women in reproductive age group, presented with HGSOC.

CASE REPORT: A 22year old and 35 year old females both presented with vague abdominal pain and mass per abdomen as their main complaints. Haematological and radiological investigations were done and diagnosed as heterogeneous ovarian malignancy and proceeded with Primary Cytoreductive surgery and later both were subjected to adjuvant chemotherapy.


Keywords


High grade serous ovarian carcinoma (HGSOC), biology, prognosis, premenopausal

Full Text:

PDF

References


Matulonis U.A., Sood A.K., Fallowfield L., Howitt B.E., Sehouli J., Karlan B.Y. Ovarian cancer. Nat. Rev. Dis. Primers. 2016; 2:16061.

Kurman R.J., Shih Ie M. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised and Expanded. Am. J. Pathol. 2016; 186:733–747.

Bowtell D.D., Böhm S., Ahmed A.A., Aspuria P.-J., Bast R.C., Jr., Beral V., Berek J.S., Birrer M.J., Blagden S., Bookman M.A. Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer. 2015; 15:668–679.

Gilbert L., Basso O., Sampalis J., Karp I., Martins C., Feng J., Piedimonte S., Quintal L., Ramanakumar A.V., Takefman J., et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: Results from the prospective DOvE pilot project. Lancet Oncol. 2012; 13:285–291.

Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I,et al. Ten year relative survival for epithelial ovarian cancer. Obstet Gynecol.2012; 120:612-618.

Webb P.M., Jordan S.J. Epidemiology of epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2017; 41:3–14.

Chang S.-J., Hodeib M., Chang J., Bristow R.E. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. Gynecol. Oncol. 2013; 130:493–498.

Chang S.-J., Bristow R.E., Ryu H.-S. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann. Surg. Oncol. 2012; 19:4059–4067.


Refbacks

  • There are currently no refbacks.